Comparison of incident hypertension between SGLT2 inhibitors vs. DPP4 inhibitors
© 2024. The Author(s)..
Although several randomized clinical trials have reported the potential benefit of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in reducing blood pressure (BP), whether SGLT2i can reduce incident hypertension is unknown. We analyzed individuals with diabetes who were newly prescribed SGLT2i or dipeptidyl peptidase 4 inhibitors (DPP4i) in a large-scale epidemiological database. The primary outcome was the incidence of hypertension. A propensity score matching algorithm was employed to compare the subsequent development of hypertension between the SGLT2i and DPP4i groups. After propensity score matching, 5708 well-balanced pairs of SGLT2i and DPP4i users were identified. SGLT2i administration was associated with a reduced risk of hypertension (HR 0.91, 95% CI: 0.84-0.97). The advantage of SGLT2i use over DPP4i use for incident hypertension was generally consistent in several sensitivity analyses, and subgroup analyses showed that SGLT2i use was significantly associated with a lower risk of hypertension in men, patients with baseline HbA1c of <7.5%, and baseline systolic blood pressure ≥127 mmHg. Our investigation using nationwide real-world data demonstrated the potential advantage of SGLT2i over DPP4i in reducing the development of hypertension in individuals with diabetes.
| Errataetall: | |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Hypertension research : official journal of the Japanese Society of Hypertension - (2024) vom: 10. Apr. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Suzuki, Yuta [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Diabetes |
|---|
| Anmerkungen: |
Date Revised 24.04.2024 published: Print-Electronic CommentIn: Hypertens Res. 2024 Apr 24;:. - PMID 38658652 Citation Status Publisher |
|---|
| doi: |
10.1038/s41440-024-01649-z |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370895959 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370895959 | ||
| 003 | DE-627 | ||
| 005 | 20240425233753.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240411s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41440-024-01649-z |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1386.xml |
| 035 | |a (DE-627)NLM370895959 | ||
| 035 | |a (NLM)38600275 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Suzuki, Yuta |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Comparison of incident hypertension between SGLT2 inhibitors vs. DPP4 inhibitors |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 24.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Hypertens Res. 2024 Apr 24;:. - PMID 38658652 | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a © 2024. The Author(s). | ||
| 520 | |a Although several randomized clinical trials have reported the potential benefit of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in reducing blood pressure (BP), whether SGLT2i can reduce incident hypertension is unknown. We analyzed individuals with diabetes who were newly prescribed SGLT2i or dipeptidyl peptidase 4 inhibitors (DPP4i) in a large-scale epidemiological database. The primary outcome was the incidence of hypertension. A propensity score matching algorithm was employed to compare the subsequent development of hypertension between the SGLT2i and DPP4i groups. After propensity score matching, 5708 well-balanced pairs of SGLT2i and DPP4i users were identified. SGLT2i administration was associated with a reduced risk of hypertension (HR 0.91, 95% CI: 0.84-0.97). The advantage of SGLT2i use over DPP4i use for incident hypertension was generally consistent in several sensitivity analyses, and subgroup analyses showed that SGLT2i use was significantly associated with a lower risk of hypertension in men, patients with baseline HbA1c of <7.5%, and baseline systolic blood pressure ≥127 mmHg. Our investigation using nationwide real-world data demonstrated the potential advantage of SGLT2i over DPP4i in reducing the development of hypertension in individuals with diabetes | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Diabetes | |
| 650 | 4 | |a Epidemiology | |
| 650 | 4 | |a Hypertension | |
| 650 | 4 | |a SGLT2 inhibitors | |
| 700 | 1 | |a Kaneko, Hidehiro |e verfasserin |4 aut | |
| 700 | 1 | |a Okada, Akira |e verfasserin |4 aut | |
| 700 | 1 | |a Komuro, Jin |e verfasserin |4 aut | |
| 700 | 1 | |a Fujiu, Katsuhito |e verfasserin |4 aut | |
| 700 | 1 | |a Takeda, Norifumi |e verfasserin |4 aut | |
| 700 | 1 | |a Morita, Hiroyuki |e verfasserin |4 aut | |
| 700 | 1 | |a Ako, Junya |e verfasserin |4 aut | |
| 700 | 1 | |a Nishiyama, Akira |e verfasserin |4 aut | |
| 700 | 1 | |a Yano, Yuichiro |e verfasserin |4 aut | |
| 700 | 1 | |a Ieda, Masaki |e verfasserin |4 aut | |
| 700 | 1 | |a Node, Koichi |e verfasserin |4 aut | |
| 700 | 1 | |a Yasunaga, Hideo |e verfasserin |4 aut | |
| 700 | 1 | |a Komuro, Issei |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Hypertension research : official journal of the Japanese Society of Hypertension |d 1996 |g (2024) vom: 10. Apr. |w (DE-627)NLM075611406 |x 1348-4214 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:10 |g month:04 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41440-024-01649-z |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 10 |c 04 | ||